Medical - Healthcare Information Services
Build Your Comparison
Side-by-side financial analysisStock Comparison
HNGE vs HIMS vs TDOC vs DOCS vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Equipment & Services
Medical - Healthcare Information Services
Medical - Healthcare Information Services
Banks - Diversified
HNGE vs HIMS vs TDOC vs DOCS vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Equipment & Services | Medical - Healthcare Information Services | Medical - Healthcare Information Services | Banks - Diversified |
| Market Cap | $5.15B | $5.89B | $1.32B | $3.75B | $896.00B |
| Revenue (TTM) | $646M | $2.37B | $2.51B | $645M | $280.33B |
| Net Income (TTM) | $-510M | $-13M | $-171M | $196M | $57.05B |
| Gross Margin | 80.8% | 67.6% | 65.6% | 89.1% | 60.0% |
| Operating Margin | -81.6% | 1.3% | -7.6% | 33.3% | 25.9% |
| Forward P/E | 26.0x | 52.6x | — | 14.0x | 14.4x |
| Total Debt | $8M | $1.26B | $1.04B | $10M | $942.38B |
| Cash & Equiv. | $208M | $229M | $781M | $219M | $343.34B |
HNGE vs HIMS vs TDOC vs DOCS vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 25 | Jun 26 | Return |
|---|---|---|---|
| Hinge Health, Inc. (HNGE) | 100 | 168.2 | +68.2% |
| Hims & Hers Health,… (HIMS) | 100 | 47.4 | -52.6% |
| Teladoc Health, Inc. (TDOC) | 100 | 106.1 | +6.1% |
| Doximity, Inc. (DOCS) | 100 | 38.5 | -61.5% |
| JPMorgan Chase & Co. (JPM) | 100 | 121.5 | +21.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HNGE vs HIMS vs TDOC vs DOCS vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
HNGE is the #2 pick in this set and the best alternative if momentum is your priority.
- +86.6% vs DOCS's -64.8%
HIMS ranks third and is worth considering specifically for growth exposure.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 59.0% revenue growth vs TDOC's -1.5%
Among these 5 stocks, TDOC doesn't own a clear edge in any measured category.
DOCS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.75
- Lower volatility, beta 0.75, Low D/E 1.1%, current ratio 6.09x
- PEG 0.27 vs JPM's 0.81
- Beta 0.75, current ratio 6.09x
JPM is the clearest fit if your priority is long-term compounding.
- 465.8% 10Y total return vs HIMS's 173.7%
- 1.9% yield; 15-year raise streak; the other 4 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs TDOC's -1.5% | |
| Value | Lower P/E (14.0x vs 14.4x), PEG 0.27 vs 0.81 | |
| Quality / Margins | 30.4% margin vs HNGE's -78.9% | |
| Stability / Safety | Beta 0.75 vs HIMS's 2.48, lower leverage | |
| Dividends | 1.9% yield; 15-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +86.6% vs DOCS's -64.8% | |
| Efficiency (ROA) | 16.5% ROA vs HNGE's -69.5%, ROIC 19.8% vs -268.2% |
HNGE vs HIMS vs TDOC vs DOCS vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
HNGE vs HIMS vs TDOC vs DOCS vs JPM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
DOCS leads in 2 of 6 categories
TDOC leads 1 • HNGE leads 0 • HIMS leads 0 • JPM leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
DOCS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 434.7x DOCS's $645M. DOCS is the more profitable business, keeping 30.4% of every revenue dollar as net income compared to HNGE's -78.9%. On growth, HNGE holds the edge at +47.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $646M | $2.4B | $2.5B | $645M | $280.3B |
| EBITDAEarnings before interest/tax | -$524M | $99M | $42M | $227M | $81.4B |
| Net IncomeAfter-tax profit | -$510M | -$13M | -$171M | $196M | $57.0B |
| Free Cash FlowCash after capex | $206M | $76M | $251M | $215M | $100.9B |
| Gross MarginGross profit ÷ Revenue | +80.8% | +67.6% | +65.6% | +89.1% | +60.0% |
| Operating MarginEBIT ÷ Revenue | -81.6% | +1.3% | -7.6% | +33.3% | +25.9% |
| Net MarginNet income ÷ Revenue | -78.9% | -0.6% | -6.8% | +30.4% | +20.4% |
| FCF MarginFCF ÷ Revenue | +31.9% | +3.2% | +10.0% | +33.3% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +47.2% | +3.8% | -2.5% | +5.1% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -73.5% | -3.0% | +32.1% | -67.7% | +16.0% |
Valuation Metrics
TDOC leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 16.0x trailing earnings, JPM trades at a 70% valuation discount to HIMS's 52.6x P/E. Adjusting for growth (PEG ratio), DOCS offers better value at 0.39x vs JPM's 0.90x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $5.1B | $5.9B | $1.3B | $3.7B | $896.0B |
| Enterprise ValueMkt cap + debt − cash | $4.9B | $6.9B | $1.6B | $3.5B | $1.50T |
| Trailing P/EPrice ÷ TTM EPS | -12.59x | 52.59x | -6.44x | 20.45x | 16.00x |
| Forward P/EPrice ÷ next-FY EPS est. | 25.96x | — | — | 13.99x | 14.40x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.39x | 0.90x |
| EV / EBITDAEnterprise value multiple | — | 43.24x | 15.81x | 16.47x | 18.36x |
| Price / SalesMarket cap ÷ Revenue | 8.75x | 2.51x | 0.52x | 5.81x | 3.20x |
| Price / BookPrice ÷ Book value/share | 14.10x | 12.80x | 0.93x | 4.20x | 2.47x |
| Price / FCFMarket cap ÷ FCF | 30.14x | 79.62x | 4.64x | — | 8.88x |
Profitability & Efficiency
DOCS leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
DOCS delivers a 19.4% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $-139 for HNGE. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), TDOC scores 6/9 vs HIMS's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -138.7% | -2.5% | -12.4% | +19.4% | +15.9% |
| ROA (TTM)Return on assets | -69.5% | -0.6% | -5.9% | +16.5% | +1.3% |
| ROICReturn on invested capital | -2.7% | +8.6% | -11.5% | +19.8% | +4.5% |
| ROCEReturn on capital employed | -135.5% | +9.4% | -10.0% | +20.7% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 6 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.02x | 2.34x | 0.75x | 0.01x | 2.60x |
| Net DebtTotal debt minus cash | -$200M | $1.0B | $259M | -$209M | $599.0B |
| Cash & Equiv.Liquid assets | $208M | $229M | $781M | $219M | $343.3B |
| Total DebtShort + long-term debt | $8M | $1.3B | $1.0B | $10M | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | — | — | -8.76x | — | 0.74x |
Total Returns (Dividends Reinvested)
Evenly matched — HNGE and HIMS and JPM each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $466 for TDOC. Over the past 12 months, HNGE leads with a +86.6% total return vs DOCS's -64.8%. The 3-year compound annual growth rate (CAGR) favors HIMS at 44.0% vs TDOC's -33.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +43.4% | -19.7% | +4.1% | -53.7% | -0.5% |
| 1-Year ReturnPast 12 months | +86.6% | -53.1% | +2.4% | -64.8% | +21.8% |
| 3-Year ReturnCumulative with dividends | +74.0% | +198.3% | -69.9% | -38.7% | +138.2% |
| 5-Year ReturnCumulative with dividends | +74.0% | +107.9% | -95.3% | -62.2% | +118.2% |
| 10-Year ReturnCumulative with dividends | +74.0% | +173.7% | -41.3% | -62.2% | +465.8% |
| CAGR (3Y)Annualised 3-year return | +20.3% | +44.0% | -33.0% | -15.0% | +33.6% |
Risk & Volatility
Evenly matched — HNGE and DOCS each lead in 1 of 2 comparable metrics.
Risk & Volatility
DOCS is the less volatile stock with a 0.75 beta — it tends to amplify market swings less than HIMS's 2.48 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HNGE currently trades 97.7% from its 52-week high vs DOCS's 26.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.32x | 2.48x | 1.85x | 0.75x | 0.94x |
| 52-Week HighHighest price in past year | $66.90 | $70.43 | $9.77 | $76.51 | $337.25 |
| 52-Week LowLowest price in past year | $30.08 | $13.74 | $4.40 | $17.16 | $262.71 |
| % of 52W HighCurrent price vs 52-week peak | +97.7% | +38.1% | +75.1% | +26.2% | +95.1% |
| RSI (14)Momentum oscillator 0–100 | 73.3 | 59.4 | 58.5 | 40.7 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 24.7M | 4.5M | 3.9M | 7.0M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: HNGE as "Buy", HIMS as "Hold", TDOC as "Hold", DOCS as "Hold", JPM as "Buy". Consensus price targets imply 47.1% upside for DOCS (target: $29) vs 0.7% for HIMS (target: $27). JPM is the only dividend payer here at 1.86% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Hold | Hold | Buy |
| Price TargetConsensus 12-month target | $74.18 | $27.00 | $7.40 | $29.47 | $339.75 |
| # AnalystsCovering analysts | 14 | 20 | 42 | 23 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +1.9% |
| Dividend StreakConsecutive years of raises | — | — | — | — | 15 |
| Dividend / ShareAnnual DPS | — | — | — | — | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.3% | +1.5% | 0.0% | +11.5% | +3.9% |
DOCS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TDOC leads in 1 (Valuation Metrics). 2 tied.
HNGE vs HIMS vs TDOC vs DOCS vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is HNGE or HIMS or TDOC or DOCS or JPM a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -1. 5% for Teladoc Health, Inc. (TDOC). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Hinge Health, Inc. (HNGE) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — HNGE or HIMS or TDOC or DOCS or JPM?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 16. 0x versus Hims & Hers Health, Inc. at 52. 6x. On forward P/E, Doximity, Inc. is actually cheaper at 14. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 27x versus JPMorgan Chase & Co. 's 0. 81x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — HNGE or HIMS or TDOC or DOCS or JPM?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +118. 2%, compared to -95. 3% for Teladoc Health, Inc. (TDOC). Over 10 years, the gap is even starker: JPM returned +465. 8% versus DOCS's -62. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — HNGE or HIMS or TDOC or DOCS or JPM?
By beta (market sensitivity over 5 years), Doximity, Inc.
(DOCS) is the lower-risk stock at 0. 75β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 233% more volatile than DOCS relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — HNGE or HIMS or TDOC or DOCS or JPM?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -1. 5% for Teladoc Health, Inc. (TDOC). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to -33. 6% for Hinge Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — HNGE or HIMS or TDOC or DOCS or JPM?
Doximity, Inc.
(DOCS) is the more profitable company, earning 30. 4% net margin versus -89. 9% for Hinge Health, Inc. — meaning it keeps 30. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 33. 3% versus -92. 9% for HNGE. At the gross margin level — before operating expenses — DOCS leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is HNGE or HIMS or TDOC or DOCS or JPM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 27x versus JPMorgan Chase & Co. 's 0. 81x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Doximity, Inc. (DOCS) trades at 14. 0x forward P/E versus 26. 0x for Hinge Health, Inc. — 12. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DOCS: 47. 1% to $29. 47.
08Which pays a better dividend — HNGE or HIMS or TDOC or DOCS or JPM?
In this comparison, JPM (1.
9% yield) pays a dividend. HNGE, HIMS, TDOC, DOCS do not pay a meaningful dividend and should not be held primarily for income.
09Is HNGE or HIMS or TDOC or DOCS or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, TDOC: -41. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between HNGE and HIMS and TDOC and DOCS and JPM?
These companies operate in different sectors (HNGE (Healthcare) and HIMS (Healthcare) and TDOC (Healthcare) and DOCS (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: HNGE is a small-cap high-growth stock; HIMS is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock; DOCS is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while HNGE, HIMS, TDOC, DOCS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.